No on-target adverse effects were identified in pivotal studies, derisking intravitreal IL-6 inhibition in inflammatory macular edema A low rate of intraocular inflammation was observed, with no events of retinal vasculitis or vascular occlusion Vamikibart Phase 3 Program Selected oular adverse events Vamikibart Phase 3 Program Summary of Ocular (Study Eye) and non-ocular adverse events MEERKAT MEERKAT SANDCAT SANDCAT 60